|

Mosunetuzumab (SC) Clinical Trials

2 actively recruiting trials across 1 location

Also known as: Mosunetuzumab, RO7030816

Pipeline

Phase 3: 1Phase 1/2: 1

Top Sponsors

  • The Lymphoma Academic Research Organisation1
  • Hoffmann-La Roche1

Indications

  • Cancer2
  • Marginal Zone Lymphoma1
  • Follicular Lymphoma1

Other1 trial

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3

Duarte, California1 trial

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma

City of Hope National Medical Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.